OBJECTIVES:  The aim of this study was to document how oncologists in the United States perceive treatment advances, the communication of information on unapproved uses of approved medicines, and assessing treatment value. METHODS:  Data were collected from a 20 minute on-line survey of United States-based oncologists recruited from an online panel. Findings were reported descriptively. RESULTS:  Oncologists (n=202) believe the greatest progress in cancer care has been with immunotherapies and targeted therapies compared with other innovations and that this trend will continue moving forward; the majority considered immunotherapies (84%) and targeted therapies (82%) “very/extremely” promising. More than three out of four oncologists surveyed (78%) would find it useful if more information about safety and efficacy of unapproved uses was available in their clinical practice.; 85% would be interested in receiving this information from biopharmaceutical manufacturers. A similar proportion (77%) indicated that they would be more likely to refer patients to clinical trials if more information on off-label uses of medicines were available. Oncologists identified the most important attributes of a value framework as the incorporation of the best available evidence, reflection of real-world treatment decision-making, and review by qualified experts. Nearly all respondents (>95%) were familiar with the NCCN Evidence Blocks and the ASCO Value Framework and found them “very/extremely” useful in decision making (71% and 63% respectively), compared to the ICER Value Framework and MSK Drug Abacus (19% and 24% respectively). It should be acknowledged that while the ICER and MSK tools are payer-focused and not developed for use by oncologists or patients, it remains important that those frameworks incorporate attributes that oncologists value. CONCLUSIONS:  Innovative medicines represent an opportunity for treatment progress in cancer care. Facilitating the exchange of information and addressing gaps in current value assessment tools and can help move towards a value-driven healthcare system that improves patient outcomes.